Introduction: Neuroendocrine tumors are an heterogeneous group of neoplasms with increasing incidence and high survival. The therapies, could be have a negative impact on nutrition and pronogsis of these patients.
Objetives: To analyze analytical and anthropometric parameters in relation to disease stage and survival.
Material and methods: An observational, retrospective and cross-sectional study that includes patients with neuroendocrine tumors. Data are collected at first nutrition appointment in Virgen de la Victoria Clinical Hospital, since 2015 to 2018.
Results: We analyzed data from 42 patients of 59.9±17.6 years of age, 47.6% males; with diagnosis of intestinal neuroendocrine tumor 35.8%, pancreatic 33%, carcinoid 11.9%, gastrinoma 14.3%, other locations 4.8%; Ki67 proliferation index medium 8.9±11.7, stages 1 and 2 95% and non-functioning (73.2%). 36.6% of the patients underwere subjected with pancreatic resection, 29.3% had bowel resection, 2.4% had another type and 31.7% had not surgery, and 28.6% had SSA; SSA + everolimus, QT or imatinib 16.8% and only QT 11.9%. Without treatment 33.3%. No evidence of disease was found in 19%, localized 19% and disseminated 61.9% with a follow-up time of 4.48±4 years. They presented diabetes mellitus previously 23.8%, 14.3% with oral antidiabetics; after diagnosis, increase a 14.3%, treated with ADOs 23.8%, insulin 9.5% and both 4.8%. 43% present steatorrhea, treatment with pancreatin 52.4%, adequate intake 62%; enteral supplements 35.8%, supplements of vitamin D 33.3% and multivitamins 33.3%. Anthropometric parameters: weight 67.4±12.2 kg (decrease of 4.8 Kg compared to usual), BMI 25.1±4.2, MM 48±11 Kg; MG 17.9±7.8 Kg (27±8.8%); AT 35.8±7.2 Kg; IMP 505±109, MB 1373±212 Kcal, AF 5.7±1.2. And analytical: Glucose 102.5±25.8 mg/dl, HbA1c 6.09±1.1, CT 174±51 mg/dl, TG 115±54 mg/dl, Albumin 3.8±0.5 mg/dl, prealbumin 26,2±7.5 mg/dl, vitamin D 26.6±12.2 mg/dl, magnesium 2.2±0.2 mg/dl. In the follow-up there were 4 deaths (9.5%).
Conclusions: Our patients have an acceptable nutritional status, some of them with supplementation. It would be advisable to perform an early screening for an adequate approach.
18 - 21 May 2019
European Society of Endocrinology